Demographic and clinical characteristics of study participants.

¶Non-reactive to methacholine up to a dose of 1.96 mg. ¶¶One individual, not subjected to methacholine, was selected based on FEV1 reversability with a value of 25%. ¶¶¶Budesonide 400 µg/day at visit 2for all users, except one individual in EOS low group with a usage of 200 µg/day. ¶¶¶¶Short acting β2-agonist is most frequently used. ¶¶¶¶¶Budesonide 320 µg/day at visit 2 for all users. †Statistically significant in comparison with EOS low and healthy controls (***P<0.001). ††Statistically significant in comparison with healthy controls (*P<0.05).